Silk–Hyaluronic Acid Laryngoplasty Outcomes: An Independent Tertiary Center Experience
The Laryngoscope · 2026
DOI: 10.1002/lary.70665 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Laryngoscope, 2026. Verfasst von Benjamin Wajsberg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Voice Center, Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Hyaluronic Acid, Laryngoplasty, Silk, Vocal Cord Paralysis. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate the safety and efficacy of silk protein–hyaluronic acid (silk‐HA) injection laryngoplasty for glottic insufficiency at an independent tertiary academic voice center and compare outcomes and complication rates with those of HA injection augmentation.
Methods
We retrospectively reviewed patients undergoing SilkVoice augmentation between June 2022 and August 2025 at a single institution. Outcomes included patient‐reported vocal improvement, emergency department visits, hospitalizations, and operative interventions. For patients with prior HA injection, silk‐HA outcomes were compared using a within‐patient design.
Results
Thirty‐three patients underwent 44 silk‐HA injections (mean age 73.4 years; 51.5% female). Outcome data were available for 29 patients (87.9%). Most procedures (95.5%) were office‐based with a mean follow‐up of 12.7 months. Overall, 86.2% of patients reported at least minimal vocal improvement and 79.3% reported partial to significant improvement. In a within‐patient comparison of 20 patients who received both silk‐HA and prior HA, median improvement scores were equivalent ( p = 0.776). Compared with a historical HA cohort from the same institution (691 patients, 1146 injections), operative intervention was significantly higher in silk‐HA (6.8% vs. 0.6%, p = 0.005); two cases were elective revisions for overaugmentation, and one occurred in the setting of lung cancer progression.
Conclusion
Silk‐HA injection laryngoplasty demonstrates safety and efficacy for glottic insufficiency with voice outcomes comparable to HA and no increase in serious adverse events despite higher operative revision rates. These findings from an independent academic voice center provide external validation supporting silk‐HA as a viable office‐based augmentation option. Level of Evidence 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cleveland Clinic Voice Center, Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Case Western Reserve University School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
- Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
ORCID-Profile: Anastasia M Christ, Sarah E Benyo, Radhika Duggal, Michael S Benninger, William S Tierney
Zitieren
APA
Wajsberg, B., Christ, A. M., Benyo, S. E., Keuchel, C. A., Duggal, R., Wu, R., Benninger, M. S., Nelson, R. C., Bryson, P. C., & Tierney, W. S. (2026). Silk–Hyaluronic Acid Laryngoplasty Outcomes: An Independent Tertiary Center Experience. The Laryngoscope. https://doi.org/10.1002/lary.70665
Vancouver
Wajsberg B, Christ AM, Benyo SE, Keuchel CA, Duggal R, Wu R, et al. Silk–Hyaluronic Acid Laryngoplasty Outcomes: An Independent Tertiary Center Experience. The Laryngoscope. 2026. doi:10.1002/lary.70665
BibTeX
@article{Wajsberg2026,
author = {Wajsberg, Benjamin and Christ, Anastasia M and Benyo, Sarah E and Keuchel, Connor A and Duggal, Radhika and Wu, Richard and Benninger, Michael S and Nelson, Rebecca C and Bryson, Paul C and Tierney, William S},
title = {Silk–Hyaluronic Acid Laryngoplasty Outcomes: An Independent Tertiary Center Experience},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.70665}
}
EUVIMED